Progression of PD-1/PD-L1 inhibitor combination therapy in pancreatic cancer
10.3760/cma.j.cn113884-20240303-00060
- VernacularTitle:PD-1/PD-L1抑制剂联合治疗胰腺癌的研究进展
- Author:
Zhuohui REN
1
;
Xiao LI
;
Zhengcai LIU
;
Shuqiang YUE
Author Information
1. 空军军医大学西京医院综合外科，西安 710032
- Keywords:
Programmed cell death 1 repoptor;
Programmed death-ligand 1;
Pancreatic cancer;
Immune checkpoint inhibitors;
Combination therapy
- From:
Chinese Journal of Hepatobiliary Surgery
2024;30(11):872-876
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death protein 1 (PD-1) and programmed death protein ligand-1 (PD-L1) play pivotal roles in maintaining immune homeostasis and a crucial link in tumour immune evasion. PD-1/PD-L1 inhibitors have achieved significant efficacy in many cancer immunotherapy, but the effect in the treatment of pancreatic cancer is limited, and the effect of monotherapy is suboptimal. The combined therapeatic effect of PD-1/PD-L1 and chemotherapy, radiotherapy, and molecular targeted therapy were explored. This article summarises the advancements in PD-1/PD-L1 inhibitor combination therapy in the treatment of pancreatic cancer.
